SAN FRANCISCO – Gilead Sciences Inc.’s breakthrough hepatitis C virus (HCV) drug Sovaldi (sofosbuvir), which gained approval in the U.S. in December and got off to a strong start despite typical slowdown of the holidays, is expected to be approved in Europe later this month, likely with favorable pricing.